Clinical Trial Update: Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating irbesartan combined with hydrochlorothiazide as first-line therapy for severe hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)
• Irbesartan (irbesartan)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hypertension | Phase 3 | Status: COMPLETED